| abstract |
The present invention relates to a method of using a biomarker to evaluate treatment of gastrointestinal inflammatory disorders using a beta 7 antagonist. More particularly, the present invention relates to a therapeutic agent for the treatment of gastrointestinal inflammatory disorders, for example, an indicator (or biomarker) for the effect, efficacy, safety, prognosis and / or capacity of a beta 7 integrin antagonist in the digestive tract- Level, the occupancy level of the drug on the digestive tract-to-recipient lymphocytes, and / or the level of beta 7 integrin receptor on the digestive tract-recipient lymphocyte. |